Abstract
Alzheimer’s disease is a neurodegenerative disorder characterized clinically by cognitive decline and pathologically by amyloid deposition and neurofibrillary changes. These neuropathological hallmarks are accompanied by reactive events including microglial activation and astrogliosis. The inflammatory response in Alzheimer’s disease brains is distinguished by a pro-inflammatory signature involving amyloid peptides1, inflammasome signaling2 and disrupted blood brain barrier3. Inflammatory changes are observed also in the cerebrospinal fluid in Alzheimer’s disease4,5. It remains unknown, however, whether the choroid plexus which produces cerebrospinal fluid and guards the brain from peripheral inflammatory insults6,7, contributes to the inflammation and pathogenesis of Alzheimer’s disease. Here we show that the choroid plexus in Alzheimer’s disease exhibits a pro-inflammatory signature with aberrant protein accumulations, which contribute to the age-dependent inflammatory changes observed in the cerebrospinal fluid. Magnetic resonance imaging reveals that the choroid plexus in patients with Alzheimer’s disease displays pathological signal and increased volume, which inversely correlates with cognitive decline. Our findings suggest that the choroid plexus, being unable to efficiently resolve inflammatory insults over the lifetime, eventually ignites and drives the aberrant inflammatory response observed in Alzheimer’s disease. These findings advance our understanding of the pathogenesis and open new vistas in the diagnostics and therapeutics of Alzheimer’s disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the European Regional Development Funds No. CZ.02.1.01/0.0/0.0/16_019/0000868 ENOCH grant (S.B., J.D., G.F., J.F., M.H., J.H., S.K. and G.B.S.), Research Infrastructure RECETOX RI grant (No LM2018121) financed by the Ministry of Education, Youth and Sports, and Operational Programme Research, Development and Innovation - CZ.02.1.01/0.0/0.0/17_043/0009632 CETOCOEN EXCELLENCE project, and the HORIZON 2020 No. 857560 (J.D., G.B.S. and Z.S.), the Czech Ministry of Health grants NV 18-04-00346 (Z.N.), NV 18-04-00455 and 00064203 (J.H.), NV19-08-00472 (Z.S. and K.S.), the No. CZ.02.1.01/0.0/0.0/16_026/0008451 INBIO grant (J.D.), NIH grant P30 AGO62429 (R.A.R.), the Barrow Neurological Foundation and the Fein Foundation (R.B.), the research infrastructure LM2018121 RECETOX grant (Z.S.), the Grant Agency of the Masaryk University No. MUNI/G/1131/2017 GAMU (Z.S.) and MUNI/A/1615/2020 (S.K.) grants, the National Cancer Institute of the NIH grant No. P30CA033572 (P.P.), the NIA U01 grant U01AG061357 (E.B.D. and N.T.S.) and the Institutional Support of Excellence 2. LF UK grant 6990332 (J.H.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB/ethical approvals were obtaine from: Czech Brain Aging Study, St. Anne's University Hospital, Brno, and Motol Hospital, Prague, Barrow Neurological Institute, Phoenix, Alzheimer's Disease Neuroimaging Initiative, Buenos Aires, Argentina, Shiley-Marcos Alzheimer's Disease Research Centre, University of California San Diego, Imperial College Parkinson's UK Brain Bank
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.